Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease
Background. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Pa...
Saved in:
Main Authors: | Antonio Vitale, Virginia Berlengiero, Jurgen Sota, Luisa Ciarcia, Nicola Ricco, Sara Barneschi, Mariam Mourabi, Giuseppe Lopalco, Chiara Marzo, Francesca Bellisai, Florenzo Iannone, Bruno Frediani, Luca Cantarini |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2020/8054961 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network
by: Carla Gaggiano, et al.
Published: (2020-01-01) -
Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives
by: Giuseppe Lopalco, et al.
Published: (2015-01-01) -
Update on the Medical Management of Gastrointestinal Behçet’s Disease
by: Giuseppe Lopalco, et al.
Published: (2017-01-01) -
Adult Onset Still's Disease and Autoinflammation
by: Petros Efthimiou, et al.
Published: (2012-01-01) -
Pulmonary Onset of Adult Onset Still’s Disease Complicated with Kikuchi Lymphadenitis
by: G. D. E. Kodithuwakku, et al.
Published: (2020-01-01)